MRD

Related by string. Mr. * * Mr Downer . Mr de Menezes . Mr. Potato Head . Mr Salmond . Mrs Gandhi . Mr Straw . Mrs McCann . Mr Rudd . Mr Turnbull . Mr Clegg . Mrs Thatcher . Mr. Popper Penguins . Mr Ahern . Mr Beazley . Mrs Snoop Dogg . Mr Bracks . Mr Brumby . Mr Hain . Mr Hoon . Mr Lenihan . Mr Iemma . Mr Ruddock . Mr Vaile . Mr Blunkett . Mr O'Farrell . Mr Rann . Mr Baillieu . Mr Qarase . Mr Combet . Mr MacAskill *

Related by context. All words. (Click for frequent words.) 45 IIIA NSCLC 45 thyroglobulin 45 pT3 44 locoregional 44 biochemical recurrence 43 CLL SLL 43 micrometastasis 43 univariate analysis 43 lymphovascular invasion 43 MDA MB 43 neoadjuvant chemotherapy 43 cytoreductive nephrectomy 43 seminal vesicle invasion 43 metastatic malignant melanoma 42 hematopoietic progenitors 42 squamous intraepithelial lesions 42 CR CRu 42 preoperative PSA 42 TIMP 41 mononuclear 41 Stage IIIb 41 renal carcinoma 41 PSMs 41 papillary RCC 41 CRp 41 TURBT 41 metastatic renal cell carcinoma 41 immunostaining 41 ovarian carcinoma 41 ASCT 41 prostate cancer CaP 40 CsA 40 Hb 40 endometrial adenocarcinoma 40 biochemical relapse 40 stage IIIB 40 T1c 40 peritoneal carcinomatosis 40 malignant phenotype 40 erythroid 40 Histological 40 locoregional disease 40 azacytidine 40 serum HCV RNA 40 integrin expression 40 CML CP 40 castrate resistant 40 univariate 40 tumor recurrence 40 Pharmacodynamic 40 Follicular Lymphoma 40 lymphoid 40 remission CR 40 refractory AML 40 HGD 40 refractory NSCLC 40 IIIb 40 activating mutation 40 breast carcinomas 39 lymphocytosis 39 pharmacodynamic PD 39 external beam radiotherapy 39 chemo immunotherapy 39 AJCC 39 MEFs 39 papillary 39 undetectable HBV DNA 39 median PFS 39 constitutively active 39 PCa 39 CR nPR 39 JCV 39 laparoscopic radical nephrectomy 39 operable breast cancer 39 DU# [002] 39 rapid virological response 39 Multivariate analysis 39 pT2 39 biliary tract cancer 39 cathepsin B 39 completely resected 39 node dissection 39 underwent resection 39 Wilcoxon rank sum 39 EORTC 39 Negative Symptom Scale 39 SWOG 39 histologically proven 39 squamous cell carcinoma SCC 39 mRCC 39 resectable 39 RECIST 39 MEND CABG II 39 relapsed AML 39 metastatic lesions 38 ERCC1 38 androgen suppression 38 neoadjuvant 38 hepatoma 38 clinicopathological features 38 bladder carcinoma 38 T1a 38 evaluable 38 RCC 38 HSCT 38 CRPC 38 clinically meaningful improvement 38 ECOG 38 Rate ORR 38 LVD 38 RECIST criteria 38 Main Outcome Measure 38 metastases 38 radiologically 38 Complete Response CR 38 pCR 38 pleomorphic 38 Glioblastoma Multiforme 38 promoter methylation 38 transthoracic echocardiography 38 urothelial 38 histologically confirmed 38 cervical lymph nodes 38 androgen deprivation 38 P = .# 38 undetectable HCV RNA 38 radical prostatectomy RP 38 refractory colorectal cancer 38 NMIBC 38 TNM staging 38 TIMP 1 38 § #.# [002] 38 cTnI 38 refractory ovarian cancer 38 hTERT 38 BiP 38 nomograms 38 ACR 38 IFN α 38 posttreatment 38 multivariate Cox 38 surgically resectable 38 1beta 38 allogeneic SCT 38 nonmetastatic prostate cancer 38 lymph node metastasis 38 p# p# 38 concurrent chemoradiation 38 NSABP B 38 urothelial carcinoma 38 cisplatin chemotherapy 38 lymphadenectomy 38 NM# [003] 38 mITT population 38 IL#B 38 elevated transaminases 38 haematologic 37 FOLPI 37 radical cystectomy 37 microbiologically evaluable 37 bispecific 37 endometrioid 37 Mutational 37 lymph node metastases 37 fludarabine cyclophosphamide 37 EOX 37 multivariate analyzes 37 chemoradiotherapy 37 gene inactivation 37 F FDG PET 37 Castration Resistant Prostate Cancer 37 sarcomatoid 37 nodal dissection 37 Bruton tyrosine kinase 37 EBMT criteria 37 1 diabetes T1D 37 TGF β1 37 carcinoma 37 CCyR 37 Histologic 37 LRR 37 concurrent chemoradiotherapy 37 % CI #.#-#.# [007] 37 progressors 37 recurrent NSCLC 37 NTx 37 Lymph node 37 ABVD 37 intact parathyroid hormone 37 immunoreactive 37 TRUS 37 thymocytes 37 LNCaP 37 randomized discontinuation 37 ug dose 37 missense mutation 37 HDACi 37 ELISA assay 37 replicon 37 renal tumors 37 cholangiocarcinoma 37 pDC 37 TOP2A 37 Supplemental Figure 37 prospectively defined 37 multicentre randomized 37 Fontan procedure 37 subthreshold 37 Grade Thickness 37 fosbretabulin 37 HGPIN 37 micrometastases 37 renal cell carcinomas 37 LRTI 37 mitomycin C 37 papillary renal cell carcinoma 37 EuroSCORE 37 transrectal ultrasound guided 37 NSCLC 37 embryonal carcinoma 37 total thyroidectomy 37 mITT 37 cisplatin vinorelbine 37 protein tyrosine kinase 37 nodal metastases 37 curative resection 37 imatinib resistant 36 Kaplan Meier analysis 36 proteolytic cleavage 36 substrate specificity 36 Kaplan Meier method 36 VGPR 36 conformal radiotherapy 36 adjuvant radiotherapy 36 E3 ligase 36 Kellgren Lawrence 36 Leydig cells 36 platinum refractory 36 allelic variants 36 #m Tc 36 neoadjuvant therapy 36 CALGB 36 hypomethylating agents 36 MetS 36 Haplotype 36 extracapsular extension 36 GTP hydrolysis 36 breast carcinoma 36 colorectal liver metastases 36 neoplasia CIN 36 colorectal adenocarcinoma 36 logistic regression models 36 PANSS Positive 36 36 MXR 36 pancreatic adenocarcinoma 36 PSA nadir 36 ZYBRESTAT TM 36 follicular lymphoma 36 SNP rs# [002] 36 mCRPC 36 lymph node involvement 36 dose melphalan 36 Syk 36 CGR 36 kinetochores 36 ERalpha 36 Mitotic 36 mutational status 36 HiPer 36 BCL2 36 Polymorphism 36 distant metastases 36 distant metastasis 36 relapsing multiple sclerosis 36 sensory neuropathy 36 SH2 domain 36 extranodal 36 polyarticular 36 bortezomib refractory 36 paragangliomas 36 cells transfected 36 EGFP 36 PFS 36 sorafenib Nexavar ® 36 pegylated interferon alfa 2b 36 Lymphocyte 36 non metastatic resectable 36 confidence intervals CIs 36 DAS# CRP 36 cardiac allograft vasculopathy 36 Catenin 36 ECOG PS 36 complete cytogenetic 36 germline mutations 36 PR1 36 Ceplene/IL-2 36 ZACTIMA 36 TGFß 36 stage IIIA 36 chemoradiation 36 RRs 36 fibrinolytic therapy 36 AML 36 MISRA C + 36 unresectable stage 36 PROCHYMAL 36 dyssynchrony 36 histopathologic examination 36 apoptotic cells 36 -#.# ± [002] 36 BCIRG 36 HER2 positive metastatic breast 36 R0 resection 36 refractory DLBCL 36 HOMA IR 35 immunohistochemistry 35 tumoral 35 RBC transfusion 35 ASCENT 35 DAS# remission 35 Tie2 35 CTEPH 35 Randomized Evaluation 35 multikinase inhibitors 35 lesional 35 dacarbazine DTIC 35 ISF# 35 MTD 35 sustained virological response 35 gemcitabine carboplatin 35 interrater reliability 35 metastatic GIST 35 Myosin 35 FDG-PET/CT 35 transgenic mice expressing 35 secretory 35 anti apoptotic proteins 35 troponins 35 Adanac Moly Corp. 35 peptide receptor 35 AST ALT 35 metaplasia 35 nonmetastatic 35 A#V 35 GVAX Pancreas Vaccine 35 etiologic 35 CMV 35 P2X 35 GBM 35 histological subtype 35 ± SD 35 metastatic pancreatic 35 achieved CCyR 35 metastatic androgen independent 35 Adenomas 35 Doppler sonography 35 MDRD 35 ERBB2 35 Metastatic 35 null mice 35 cells mcL 35 Fv 35 neoadjuvant treatment 35 talabostat 35 hip resurfacing arthroplasty 35 RECIST Response Evaluation Criteria 35 mediated apoptosis 35 Fig. 3A 35 ploidy 35 transactivation 35 adipogenic 35 μg liter 35 nonparametric 35 CTLs 35 Kaplan Meier estimates 35 Fig. 2c 35 Antigen CEA 35 % CI #.#-#.# [003] 35 histologic subtype 35 hypogonadal 35 WTX 35 peritumoral 35 vesicle fusion 35 CIMZIA TM 35 peritoneal 35 transferase 35 ACAT 35 pelvic lymphadenectomy 35 lung carcinomas 35 VTP 35 detectable HCV RNA 35 PTI CORR 35 focal adhesion 35 phosphatidylinositol 35 intratumoral injection 35 DM2 35 steroidogenesis 35 PU.1 35 nodular BCC 35 SUD 35 Stage IIIA 35 Nampt 35 mRS 35 PRR 35 postoperative chemotherapy 35 transduced 35 nucleolin 35 radical nephrectomy 35 preoperative chemotherapy 35 adenylate kinase 35 PAX5 34 Supplementary Figs 34 Chronic lymphocytic leukemia 34 neointimal 34 Zevalin consolidation 34 pentamidine 34 histology 34 pegylated interferon ribavirin 34 N0 34 histopathological 34 Anticalin ® 34 paclitaxel carboplatin 34 pericardial effusion 34 EBRT 34 GlcNAc 34 BEXXAR Therapeutic Regimen 34 Bayer HealthCare Onyx Pharmaceuticals 34 NMDA 34 idiopathic membranous nephropathy 34 nucleolar 34 thyroid hormone receptor 34 perfusion abnormalities 34 cervical carcinoma 34 eukaryotic translation 34 FDG PET imaging 34 H#.# 34 MVax 34 T#M mutation 34 cell carcinoma 34 VEGF receptor 34 T#C [001] 34 metaphase 34 interferon γ 34 CD#b 34 degenerative lumbar 34 CZP 34 Low Density Residential 34 Prognostic Index 34 peptidase 34 AAB 34 β actin 34 squamous 34 gene rearrangements 34 topoisomerase 34 FOLFIRINOX 34 esophageal varices 34 metastatic cancer 34 histone H3 34 acinar 34 eIF2 34 OvaRex MAb 34 beta tubulin 34 intraventricular 34 p# mitogen activated 34 SVR4 34 murine 34 GIST 34 rs# [004] 34 Acute Myelogenous Leukemia AML 34 Doxil ® 34 ACR BI RADS 34 MTE 34 fig. S3 34 prognostic variables 34 bone scintigraphy 34 schizoaffective disorder bipolar 34 Unresectable 34 microglial 34 chromosome #p#.# 34 Panoro Minerals 34 Main Outcome Measures 34 tumor regressions 34 ENGAGE AF TIMI 34 TAXUS V 34 Monocyte 34 TAAs 34 CRQ 34 DLC1 34 MEK1 34 aortoiliac 34 #I [003] 34 ABR 34 34 ER CHOP 34 iNOS 34 Rab5 34 myocardial revascularization 34 mineralocorticoid receptor 34 Flt3 34 PPMO 34 patients evaluable 34 cytoplasmic tail 34 intracellular Ca 2 34 protein isoforms 34 DSBs 34 cytokinesis 34 IL 1ß 34 resection 34 Elitek 34 effector memory 34 RARS 34 statistically significant p = 34 iPTH 34 Phosphorylation 34 U# [007] 34 plasmacytoid 34 endocytic 34 glycophorin 34 HZW 34 catecholamine 34 prostate cancer HRPC 34 renal pelvis 34 Mangkolemba 34 MAXIMA 34 Surgical resection 34 GBD 34 #R# [010] 34 CArG 34 ETDRS 34 RVR 34 mitotic 34 sipuleucel T 34 NADiA TM 34 dinucleotide 34 scavenger receptor 34 Skip Galan 34 Prognostic Value 34 liver resection 34 mucinous 34 ADRP 34 Releasing Factor 34 pancreatic carcinoma 34 adjuvant therapy 34 JWL 34 kimberlite lithologies 33 TACE 33 median CD4 33 subscale scores 33 pulmonary metastases 33 liver metastasis 33 MyoD 33 PEPP 33 biventricular 33 induced apoptosis 33 non hematologic toxicities 33 CEUS 33 VMP 33 c myb 33 adjuvant tamoxifen 33 adjuvant systemic 33 FEO 33 Primary endpoints 33 ubiquitination 33 tyrosine phosphorylation 33 beta globin 33 DXers 33 Timed Walk 33 Metastatic Renal Cell Carcinoma 33 succinate dehydrogenase 33 mRNA encoding 33 stage IIIb IV 33 regulated kinase 33 C.# 33 n = 33 InN 33 metastatic gastric 33 troponin T 33 Fig. 3d 33 RMR RHR RFR RDR 33 ACRIN 33 Cutaneous T 33 RENAL 33 steroidogenic 33 tipranavir ritonavir 33 cytotoxic conjugate 33 EDSS score 33 bone metastasis 33 follicular thyroid cancer 33 apoptotic 33 transcriptional regulation 33 cutaneous squamous cell carcinoma 33 cyclin dependent kinase 33 ubiquitin ligase 33 NYHA functional class 33 trial evaluating Prochymal 33 intraabdominal 33 heterozygotes 33 CCL2 33 Declares Dividend Quick Facts 33 SPECIFICS Cotton Valley 33 bioelectrical impedance analysis 33 Multicenter 33 thymic 33 morphogen 33 cAMP dependent 33 PITX2 methylation 33 biopsy Gleason 33 Fibromyalgia syndrome 33 recurrent metastatic 33 ATTAIN 33 prospective nonrandomized 33 Zyclara 33 sulfide zones 33 chemokine receptor 33 BCG refractory 33 Mammographic 33 Guided Focused Ultrasound 33 RGC 33 dimerization 33 evaluable subjects 33 VQuad ™ 33 #.#E [003] 33 Fig. 3b 33 angiographically 33 Oncotype DX Recurrence Score 33 malignant ovarian 33 thymocyte 33 unresectable 33 intravitreal bevacizumab 33 luminal narrowing 33 PCWP 33 RTOG 33 resected 33 PEQ 33 serum alkaline phosphatase 33 CRC 33 histologic findings 33 LITHIA MOTORS 33 IIIA 33 missense mutations 33 nodal metastasis 33 subscore 33 tolerogenic 33 Severity Index PASI 33 Preoperative 33 amino acid substitutions 33 metastatic disease 33 p = #.# [003] 33 Appendix VII 33 Radiographic 33 CMZ 33 recurrent GBM 33 Appropriateness Criteria 33 Foxp3 33 overexpressing cells 33 Degenerative Disc Disease 33 hypothalamic pituitary 33 #,#,#,# [011] 33 SMCs 33 ADCP 33 PARD 33 aneurysmal 33 DAS# scores 33 p = #.# [002] 33 SUO 33 protein tyrosine phosphatase 33 hydronephrosis 33 NS3 33 CD8 + 33 plasma renin activity 33 ABCB1 33 Cystatin C 33 PRDs 33 INACTINE 33 p = 33 PPWU 33 gastroduodenal 33 RETI 33 3 registrational trial 33 transitional cell carcinoma 33 IFN alfa 33 CDAI 33 phospho 33 SIMPADICO 33 SC1 33 integrin alpha 33 ImmuKnow assay 33 syntaxin 33 pDCs 33 metastatic bladder 32 ISOCOUNTRY3 32 C1 C2 32 prospectively randomized 32 differentiated thyroid carcinoma 32 HAZ 32 REVIVE Diabetes 32 THLD 32 KKW 32 FMK 32 PSM 32 Fig. 2A 32 AtherOx 32 renal allograft 32 32 potent inhibition 32 myocardial viability 32 SSII 32 CRMP 32 MCID 32 gene polymorphisms 32 Microtubule 32 prospective randomized multicenter 32 RTSA 32 asynchronous motors 32 metastatic RCC 32 Oncogenic 32 YFP 32 CALB 32 GAF 32 cytokine refractory 32 histopathologic 32 atherothrombotic 32 femoral neck fracture 32 HDRS 32 glycosyltransferase 32 CTGF 32 RGCs 32 clinicopathological 32 epithelial ovarian 32 CD1d 32 Free Survival PFS 32 fig. S1 32 extracapsular 32 HIF 1a 32 androgen receptor AR 32 MMSE score 32 CORD II 32 IABP 32 TLR antagonist 32 ERK1 2 32 #a #a [003] 32 lytic 32 Inductance 32 cotransporter 32 homodimers 32 MIL HDBK 32 RII 32 axillary lymph nodes 32 adipocyte 32 squamous carcinoma 32 myocardial necrosis 32 motoneurons 32 caveolin 32 Cinacalcet HCl 32 aT cell 32 GWD 32 PI3K Akt 32 chemoradiation therapy 32 QRS duration 32 UPDRS Part III 32 clinically evaluable CE 32 Ikona 32 LUP 32 prior nephrectomy 32 nonoperative 32 linear regression analyzes 32 adjuvant radiation 32 § #.#.# [002] 32 multivariable Cox 32 monocytes macrophages 32 Kaplan Meier survival 32 Notch1 32 ESR1 32 DRC LVS 32 medullary thyroid cancer 32 GCGC 32 eosin 32 intravenous belinostat 32 #F [005] 32 digital subtraction angiography 32 Interrater reliability 32 TEVAR 32 Neutropenia 32 fig. S6 32 coexpression 32 Natalizumab 32 polycystin 1 32 T Cell Lymphoma 32 NIHSS 32 chlortetracycline 32 NAIC RBC 32 Kantarjian H 32 VVI 32 polypeptide 32 Rear Suspension 32 NSABP 32 TDO 32 hepatocellular cancer 32 colorimetric assay 32 Supplementary Fig 32 beta subunit 32 Baner Balewadi 32 Echocardiographic 32 GAPDH 32 MAP#K# 32 neoadjuvant chemoradiotherapy 32 COPERNICUS 32 GCMI 32 serine protease 32 B lymphocytes 32 Abcourt Mines 32 FVT 32 Kemetco 32 EMEW plant 32 patientswith 32 Conceptual Design 32 T2 weighted images 32 parenchymal 32 mitogen activated protein kinase 32 TRK 32 EBNA1 32 proximal humeral fractures 32 mediated inhibition 32 prospectively stratified 32 IGF 1R 32 C3A 32 CFQ R 32 MDS 32 DTIC 32 Hazard Ratio 32 DSMC 32 E#F# 32 antiretroviral naïve 32 IL6 32 MISRA 32 clinicopathologic 32 Percutaneous Coronary Interventions 32 BMP receptor 32 1i 32 malignant pleural effusion 32 infantile onset 32 chromosome #p# [002] 32 advanced pancreatic neuroendocrine 32 Radiation Therapy Oncology 32 cytokine receptors 32 extracranial 32 SLN biopsy 32 tubulin 32 DFSP 32 SiliconSmart 32 ACC AHA 32 Fig. 1D 32 Fig. 1a 32 CpG 32 Soft Tissue Sarcoma 32 RS1 32 RYL 32 ^ sup ^ 32 pancreatic islet cell 32 oncolytic vaccine 32 Lyncorp Drilling Services 32 L#R 32 intralesional 32 PDZ domain 32 #C# [002] 32 TS 32 COPAXONE 32 mediastinal 31 collagenous colitis 31 EMEW 31 c Myb 31 edotreotide 31 ± SEM 31 PLAT 31 Linear Metals Corporation 31 process flowsheet 31 MAGE 31 TC 31 Monoamine Oxidase 31 TSX VEN 31 BPRS 31 Tf 31 DGR 31 PNES 31 Lock Loop PLL 31 H#K#me# 31 VMAT2 31 extracellular domain 31 chemokine 31 AIQ 31 N methyl 31 AAQ 31 cytoplasmic domain 31 DGGE 31 BPSK 31 Psoriasis Area 31 T1 weighted 31 Gag protein 31 ductal carcinomas 31 SAH 31 phosphorylase 31 metastatic 31 transgenic mouse model 31 IPMN 31 intersected weakly mineralized 31 6S RNA 31 M1 muscarinic 31 unresectable Stage III 31 Al#O# 31 Mammastatin Serum Assay 31 RBV 31 colocalization 31 H#K# [002] 31 splice variants 31 locked loops PLLs 31 DASC 31 TAp# 31 gamma H2AX 31 Vein Fault # 31 MLNM 31 WK# [001] 31 multimodality therapy 31 Fig. 1C 31 rho = 31 COR 31 TNFR 31 intimal 31 IEC #-#-# [001] 31 Doppler ultrasonography 31 TRAS 31 AT1 31 GABAergic interneurons 31 resected pancreatic cancer 31 IKDC 31 ERBITUX Cetuximab 31 IKZF1 31 COOH terminal 31 msec 31 submucosal 31 unmethylated 31 prospective multicenter study 31 Diabetic Foot Ulcer 31 Aggrenox ® 31 Eg5 31 Runx1 31 Fig. 1A 31 SOCS3 31 PGCs 31 Hematologic 31 Zyvax 31 functional mitral regurgitation 31 Preoperatively 31 cutaneous melanoma 31 TSXV Ticker Symbol 31 Pink Sheets RCCH 31 Differentially 31 co stimulatory molecules 31 radical retropubic prostatectomy 31 SMRP 31 Histone H3 31 VEGFR2 31 basal cell carcinoma BCC 31 heterochromatic 31 Figure S4 31 intracellular signaling 31 Squamous Cell Carcinoma 31 DCE MRI 31 refractory metastatic 31 BRCA deficient 31 Systemic Sclerosis 31 glioblastoma GBM 31 MRNA 31 IECs 31 amino acid substitution 31 phosphorothioate 31 MIVI TRUST 31 NMDAR 31 R1E 31 nerve conduction velocity 31 striatal dopamine 31 intraepithelial 31 hepatocellular carcinoma 31 ovarian cancer biomarker 31 Linear Actuator 31 β2 31 catenin 31 adrenoceptor 31 Guides FY# Quick Facts 31 PKG 31 DDIC 31 TCR 31 immunofluorescence 31 Exh 31 tipranavir r 31 oligomeric 31 HAQ DI 31 ERK signaling 31 DLQI

Back to home page